UNSPSC 51162722: Moguisteine

This classification denotes a mucolytic agent with the molecular formula C16H21NO5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 6Y556547YY, chemically known as 3-thiazolidinepropanoic acid, 2-((2-methoxyphenoxy)methyl)-beta-oxo-, ethyl ester, (+-)- but more generally known as moguisteine, which bears US NIH Compound Identifier 65935. European Medicines Agency schedules Moguisteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09038MIG.

UNSPSC 51162722 Moguisteine is a Commodity code under which state and local governments procure naloxone, drug deactivation systems, and other pharmaceutical products—including both controlled substances used in harm-reduction and community health programs and generic multi-source pharmaceuticals for broader distribution through government healthcare facilities. Recent solicitations show county health departments and cooperative purchasing alliances buying naloxone kits and safe drug disposal systems in volume, as well as manufacturers responding to multi-state RFPs for generic pharmaceutical supply agreements. The work spans both emergency medical response (naloxone as an overdose reversal agent) and ongoing pharmaceutical inventory management for health departments and their partner facilities.

Issuing bodies include county health departments and state-administered cooperative purchasing alliances. Seminole County, Florida—a representative county-level buyer—issued an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (Solicitation Number S1070000015802) posted January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with a response deadline of March 26, 2026. The geographic spread is limited in the available recent activity to Florida and the Minnesota-Oregon region, though MMCAP's multi-state purchasing model suggests broader participation across cooperative member jurisdictions.